Kiromic BioPharma, Inc. (OTCPK: KRBP.Q)
Health Care · Biotechnology · US
$—
— today · — 1Y
Kiromic BioPharma, Inc. (OTCPK: KRBP.Q) operates in the Biotechnology industry within the Health Care sector. The company is valued at $157.00 and employs 44 people.
trading between 0.00 and 0.04.
Tweenvest scores Kiromic BioPharma, Inc. across four factors: quality 4/100. Its strongest factor is quality.
KRBP.Q price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $157.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.17
- Dividend yield
- —
- Beta (5Y)
- 1.01
- 52-week high
- $0.04
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.57M
- Employees
- 44
- Next earnings
- —
About Kiromic BioPharma, Inc.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
- Founded
- 2006
- Listed since
- Oct 16, 2020
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.